NCT04256317 2026-03-18
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
Clinical Trials
24 trialsNCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT06860269 2026-02-10
GRAALL-2024
Assistance Publique - Hôpitaux de Paris
Phase 2/3 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT06788756 2025-12-16
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06378138 2025-11-21
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3 Recruiting
NCT07202052 2025-10-07
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University
Phase 2/3 Recruiting
NCT07202065 2025-10-07
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University
Phase 2/3 Recruiting
NCT07202078 2025-10-07
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University
Phase 2/3 Recruiting
NCT06855810 2025-08-26
CCCG-TALL-2025
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT06882057 2025-08-26
CCCG-LR-B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT03937544 2025-05-29
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
National University of Malaysia
Phase 2/3 Recruiting
NCT06756152 2025-01-01
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT02131753 2024-08-22
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
University of Giessen
Phase 2/3 Recruiting
NCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT05678621 2024-04-19
RATIONALISE
Monash University
Phase 2/3 Recruiting
NCT05939180 2024-04-09
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT01949129 2024-01-16
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
St. Anna Kinderkrebsforschung
Phase 2/3 Recruiting
NCT05805098 2023-04-07
VHA
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT05404906 2022-08-19
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT03793517 2020-03-10
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Peking University People's Hospital
Phase 2/3 Recruiting
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting